Precision BioSciences (NASDAQ:DTIL) Announces Quarterly Earnings Results

Precision BioSciences (NASDAQ:DTIL) released its quarterly earnings data on Wednesday. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.08, Fidelity Earnings reports. The business had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $8.18 million.

DTIL stock traded down $0.67 on Thursday, reaching $8.76. 1,408 shares of the company traded hands, compared to its average volume of 123,990. Precision BioSciences has a one year low of $8.70 and a one year high of $19.00. The firm’s fifty day simple moving average is $12.72.

A number of research firms have recently commented on DTIL. BTIG Research began coverage on Precision BioSciences in a research note on Friday, August 9th. They issued a “buy” rating and a $22.00 target price for the company. HC Wainwright began coverage on Precision BioSciences in a research note on Tuesday, July 16th. They issued a “buy” rating and a $21.00 target price for the company. Goldman Sachs Group began coverage on Precision BioSciences in a research note on Monday, April 22nd. They issued a “buy” rating and a $24.00 target price for the company. Barclays began coverage on Precision BioSciences in a research note on Monday, April 22nd. They issued an “overweight” rating and a $24.00 target price for the company. Finally, JPMorgan Chase & Co. initiated coverage on Precision BioSciences in a research note on Monday, April 22nd. They issued an “overweight” rating and a $23.00 target price for the company. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $22.80.



Precision BioSciences Company Profile

Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.

Featured Article: What is the Dividend Aristocrat Index?

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.